204 related articles for article (PubMed ID: 25808628)
1. Specific Preferences in Lineage Choice and Phenotypic Plasticity of Glioma Stem Cells Under BMP4 and Noggin Influence.
Videla Richardson GA; Garcia CP; Roisman A; Slavutsky I; Fernandez Espinosa DD; Romorini L; Miriuka SG; Arakaki N; Martinetto H; Scassa ME; Sevlever GE
Brain Pathol; 2016 Jan; 26(1):43-61. PubMed ID: 25808628
[TBL] [Abstract][Full Text] [Related]
2. EGFR/FOXO3a/BIM signaling pathway determines chemosensitivity of BMP4-differentiated glioma stem cells to temozolomide.
Ciechomska IA; Gielniewski B; Wojtas B; Kaminska B; Mieczkowski J
Exp Mol Med; 2020 Aug; 52(8):1326-1340. PubMed ID: 32788653
[TBL] [Abstract][Full Text] [Related]
3. NFAT1-Mediated Regulation of NDEL1 Promotes Growth and Invasion of Glioma Stem-like Cells.
Jiang Y; Song Y; Wang R; Hu T; Zhang D; Wang Z; Tie X; Wang M; Han S
Cancer Res; 2019 May; 79(10):2593-2603. PubMed ID: 30940662
[TBL] [Abstract][Full Text] [Related]
4. Bone morphogenetic protein 4 inhibits cell proliferation and induces apoptosis in glioma stem cells.
Zhou Z; Sun L; Wang Y; Wu Z; Geng J; Miu W; Pu Y; You Y; Yang Z; Liu N
Cancer Biother Radiopharm; 2011 Feb; 26(1):77-83. PubMed ID: 21355779
[TBL] [Abstract][Full Text] [Related]
5. Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro.
Huang Q; Zhang QB; Dong J; Wu YY; Shen YT; Zhao YD; Zhu YD; Diao Y; Wang AD; Lan Q
BMC Cancer; 2008 Oct; 8():304. PubMed ID: 18940013
[TBL] [Abstract][Full Text] [Related]
6. Lineage-Restricted OLIG2-RTK Signaling Governs the Molecular Subtype of Glioma Stem-like Cells.
Kupp R; Shtayer L; Tien AC; Szeto E; Sanai N; Rowitch DH; Mehta S
Cell Rep; 2016 Sep; 16(11):2838-2845. PubMed ID: 27626655
[TBL] [Abstract][Full Text] [Related]
7. Aberrant mesenchymal differentiation of glioma stem-like cells: implications for therapeutic targeting.
Balasubramaniyan V; Vaillant B; Wang S; Gumin J; Butalid ME; Sai K; Mukheef F; Kim SH; Boddeke HW; Lang F; Aldape K; Sulman EP; Bhat KP; Colman H
Oncotarget; 2015 Oct; 6(31):31007-17. PubMed ID: 26307681
[TBL] [Abstract][Full Text] [Related]
8. CD133+ glioblastoma stem-like cells induce vascular mimicry in vivo.
Chiao MT; Yang YC; Cheng WY; Shen CC; Ko JL
Curr Neurovasc Res; 2011 Aug; 8(3):210-9. PubMed ID: 21675958
[TBL] [Abstract][Full Text] [Related]
9. Acidic stress promotes a glioma stem cell phenotype.
Hjelmeland AB; Wu Q; Heddleston JM; Choudhary GS; MacSwords J; Lathia JD; McLendon R; Lindner D; Sloan A; Rich JN
Cell Death Differ; 2011 May; 18(5):829-40. PubMed ID: 21127501
[TBL] [Abstract][Full Text] [Related]
10. Fatty acid binding protein 7 as a marker of glioma stem cells.
Morihiro Y; Yasumoto Y; Vaidyan LK; Sadahiro H; Uchida T; Inamura A; Sharifi K; Ideguchi M; Nomura S; Tokuda N; Kashiwabara S; Ishii A; Ikeda E; Owada Y; Suzuki M
Pathol Int; 2013 Nov; 63(11):546-53. PubMed ID: 24274717
[TBL] [Abstract][Full Text] [Related]
11. Targeting glioma stem cells: a novel framework for brain tumors.
Binello E; Germano IM
Cancer Sci; 2011 Nov; 102(11):1958-66. PubMed ID: 21848914
[TBL] [Abstract][Full Text] [Related]
12. LGR5 is a proneural factor and is regulated by OLIG2 in glioma stem-like cells.
Mao XG; Song SJ; Xue XY; Yan M; Wang L; Lin W; Guo G; Zhang X
Cell Mol Neurobiol; 2013 Aug; 33(6):851-65. PubMed ID: 23793848
[TBL] [Abstract][Full Text] [Related]
13. Repurposing FDA approved drugs inhibiting mitochondrial function for targeting glioma-stem like cells.
Datta S; Sears T; Cortopassi G; Woolard K; Angelastro JM
Biomed Pharmacother; 2021 Jan; 133():111058. PubMed ID: 33378970
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-30a suppresses self-renewal and tumorigenicity of glioma stem cells by blocking the NT5E-dependent Akt signaling pathway.
Peng L; Ming Y; Zhang L; Zhou J; Xiang W; Zeng S; He H; Chen L
FASEB J; 2020 Apr; 34(4):5128-5143. PubMed ID: 32067282
[TBL] [Abstract][Full Text] [Related]
15. Glioma stem cells-derived exosomes promote the angiogenic ability of endothelial cells through miR-21/VEGF signal.
Sun X; Ma X; Wang J; Zhao Y; Wang Y; Bihl JC; Chen Y; Jiang C
Oncotarget; 2017 May; 8(22):36137-36148. PubMed ID: 28410224
[TBL] [Abstract][Full Text] [Related]
16. Stem cell signature in glioblastoma: therapeutic development for a moving target.
Nakano I
J Neurosurg; 2015 Feb; 122(2):324-30. PubMed ID: 25397368
[TBL] [Abstract][Full Text] [Related]
17. Indoleamine 2,3-dioxygenase 1 is highly expressed in glioma stem cells.
Ozawa Y; Yamamuro S; Sano E; Tatsuoka J; Hanashima Y; Yoshimura S; Sumi K; Hara H; Nakayama T; Suzuki Y; Yoshino A
Biochem Biophys Res Commun; 2020 Apr; 524(3):723-729. PubMed ID: 32035622
[TBL] [Abstract][Full Text] [Related]
18. Tanshinone IIA inhibits the growth, attenuates the stemness and induces the apoptosis of human glioma stem cells.
Yang L; Guo H; Dong L; Wang L; Liu C; Wang X
Oncol Rep; 2014 Sep; 32(3):1303-11. PubMed ID: 24970314
[TBL] [Abstract][Full Text] [Related]
19. A new 2-pyrone derivative, 5-bromo-3-(3-hydroxyprop-1-ynyl)-2H-pyran-2-one, suppresses stemness in glioma stem-like cells.
Kim RK; Kim MJ; Yoon CH; Lim EJ; Yoo KC; Lee GH; Kim YH; Kim H; Jin YB; Lee YJ; Cho CG; Oh YS; Gye MC; Suh Y; Lee SJ
Mol Pharmacol; 2012 Sep; 82(3):400-7. PubMed ID: 22648970
[TBL] [Abstract][Full Text] [Related]
20. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells.
Piccirillo SG; Reynolds BA; Zanetti N; Lamorte G; Binda E; Broggi G; Brem H; Olivi A; Dimeco F; Vescovi AL
Nature; 2006 Dec; 444(7120):761-5. PubMed ID: 17151667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
